This now means the trial has achieved a key milestone of 100 participants enrolled: almost half of their 210-participant recruitment target. They are also preparing to open four new German sites, with more planned across Europe.
What is the Tiger clinical trial?
TIGER aims to be the largest trial to date comparing treatments for haemorrhages related to wet age-related macular degeneration (AMD), a complication which leads to permanent vision loss if left untreated.
What is wet AMD?
Wet AMD is the less common but faster progressing type of AMD. AMD is a condition associated with ageing which is characterised by loss of central vision, due to damage to the macula (a highly concentrated area of light-sensitive cells at the back of the eye, which are vital for seeing detail).
Wet AMD can develop in those who already have dry AMD, and is caused by abnormal new blood vessels leaking blood or fluids, in turn causing scarring to the macula. In some people this can also cause haemorrhaging in the eye.
Stay in the loop
on eye research breakthroughs, inspiring real life stories and more...
What is the trial hoping to achieve?
TIGER is aiming to establish which available treatment has the best outcome for patients. There is currently no specific licensed treatment for this type of haemorrhage, and up until now there have been no trials with the capacity to determine the best way of managing them. One reason for this is that no other trial has had a big enough population to determine the answer to this question, so it’s excellent to see that TIGER is reaching important recruitment milestones.
Related content
